Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34133718/

Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. Previous attempts to identify unique pathogenic...

SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34134766/

doi: 10.1186/s40364-021-00296-7. 1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2 Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. 3 Department of...

Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34110512/

Nowadays, several novel agents have been introduced in the treatment of multiple myeloma, not only resulting in high response rates and prolonged survival but also offering good quality of life....

Multiple Myeloma: From Baby Steps to Giant Strides

Source : https://ascopubs.org/doi/10.1200/OP.21.00327

The past three decades have witnessed major paradigm shifts in the management of multiple myeloma (MM), resulting in significant improvements not only in the survival from the diagnosis but also...

Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift

Source : https://ascopubs.org/doi/full/10.1200/OP.21.00032

Multiple myeloma (MM) is a genetically heterogenous disease and remains mostly incurable with a small group of patients achieving long-term disease remission. The past decade witnessed enormous efforts to break...